Capsaicin Effect on Cytokines Profile in Dyslipidemia

• Status: Unknown status
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The increased mortality from cardiovascular disease has a significant impact on the population, and the prevalence of these diseases it become one of the major problems, since it is the leading cause of mortality and 1 in 3 Mexicans suffer from cardiovascular disease according ENSANUT; the above is attributed to the increase of diseases associated with an inflammatory process accelerated as obesity, dyslipidemia, hypertension (SAH) and diabetes mellitus (DM).

The cholesterol is a major risk factor in the development of cardiovascular disease, and in turn increases the chances of death; however, the treatment of choice is based on changes in lifestyle, which for most people are difficult to maintain long-term. As for the drug therapy treated with drugs many people do not achieve their therapeutic goals, and therefore the inflammatory condition that underlies this disease remains.

Recent studies have focused on the possible role of capsaicin in the inflammatory state through the agonistic effect it has on TRPV1. It has demonstrated the antiinflammatory activity of capsaicin to enhance inflammation by free fatty acids (FFA) and reducing the expression of certain genes involved in this process induced. Capsaicin is a natural choice and well tolerated with few side effects limited to the gastrointestinal tract such as dyspepsia and intestinal irregularity, for the above is of interest to evaluate the effect of capsaicin on the profile of inflammatory cytokines in individuals with dyslipidemia.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guadalajara
• Collaborators: LN. Jessica Lucia Barajas Vega; PhD. Teresa Arcelia Garcia Cobian
• Treatments: Capsaicin; Magnesium Oxide

Criteria

Inclusion Criteria:

• diagnosis of dyslipidemia at the time of screening

• BMI of 25 kg /m2 to 34.9 kg / m2

• Without drug treatment in the last three months

• Signature of consent information in writing

Exclusion Criteria:

• Pregnant or lactating

• Total cholesterol ≥ 239 mg / dL, ≥400 TG, LDL-C ≥139

• Other inflammatory diseases

• consumption of some type of supplement

• Diagnosis or history of kidney or liver disease ∞ History of hypersensitivity to the compounds used in the study